

# Carlos Fernandez-Del Castillo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10453342/publications.pdf>

Version: 2024-02-01

315  
papers

37,352  
citations

3731

89  
h-index

3106

187  
g-index

324  
all docs

324  
docs citations

324  
times ranked

20826  
citing authors

#	ARTICLE	IF	CITATIONS
1	A risk-adjusted analysis of drain use in pancreaticoduodenectomy: Some is good, but more may not be better. <i>Surgery</i> , 2022, 171, 1058-1066.	1.9	5
2	The Fistula Risk Score Catalog. <i>Annals of Surgery</i> , 2022, 275, e463-e472.	4.2	32
3	A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer. <i>Annals of Surgery</i> , 2022, 275, 391-397.	4.2	15
4	Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, 378-385.	4.2	50
5	Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, e502-e509.	4.2	6
6	Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy. <i>European Radiology</i> , 2022, 32, 2470-2480.	4.5	9
7	Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. <i>Surgery</i> , 2022, 171, 1379-1387.	1.9	7
8	Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, e518-e526.	4.2	11
9	ABO blood group distribution and risk of malignancy in patients undergoing resection for intraductal papillary mucinous neoplasm (IPMN). <i>Pancreatology</i> , 2022, 22, 264-269.	1.1	4
10	Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria. <i>Annals of Surgery</i> , 2022, 276, 215-221.	4.2	5
11	Number of Worrisome Features and Risk of Malignancy in Intraductal Papillary Mucinous Neoplasm. <i>Journal of the American College of Surgeons</i> , 2022, 234, 1021-1030.	0.5	9
12	Abstract SY12-04: Multicellular spatial community featuring a novel neuronal-like malignant phenotype is enriched in pancreatic cancer after neoadjuvant chemotherapy and radiotherapy. <i>Cancer Research</i> , 2022, 82, SY12-04-SY12-04.	0.9	0
13	Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. <i>JCO Oncology Practice</i> , 2022, 18, e1587-e1593.	2.9	6
14	Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2021, 274, e134-e142.	4.2	28
15	Simulated Volume-Based Regionalization of Complex Procedures. <i>Annals of Surgery</i> , 2021, 274, 312-318.	4.2	15
16	Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?. <i>Annals of Surgery</i> , 2021, 274, e980-e987.	4.2	22
17	Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 182-191.	6.3	49
18	Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic <i>KLF4</i> mutations predominantly in low-grade regions. <i>Gut</i> , 2021, 70, 928-939.	12.1	48

#	ARTICLE	IF	CITATIONS
19	Extracellular Vesicle Analysis Allows for Identification of Invasive IPMN. <i>Gastroenterology</i> , 2021, 160, 1345-1358.e11.	1.3	60
20	Response to: Re: Management of the pancreatic transection plane after left (distal) pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). <i>Surgery</i> , 2021, 169, 480-481.	1.9	2
21	Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2859-2870.	1.7	8
22	Prognostic impact of chemoradiation-related lymphopenia in patients with locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 439-439.	1.6	0
23	Patient and Caregiver Considerations and Priorities When Selecting Hospitals for Complex Cancer Care. <i>Annals of Surgical Oncology</i> , 2021, 28, 4183-4192.	1.5	11
24	Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. <i>Molecular Imaging and Biology</i> , 2021, 23, 456-466.	2.6	22
25	The use of elevated circulating hepatocyte growth factor (HGF) level as a potential prognostic biomarker in locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 429-429.	1.6	2
26	Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation. <i>Annals of Surgical Oncology</i> , 2021, 28, 4592-4601.	1.5	9
27	Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection. <i>Clinical Cancer Research</i> , 2021, 27, 2807-2815.	7.0	12
28	Assessment of the Long-Term Impact of Pancreatoduodenectomy on Health-Related Quality of Life Using the EORTC QLQ-PAN26 Module. <i>Annals of Surgical Oncology</i> , 2021, 28, 4216-4224.	1.5	11
29	Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula development. <i>Surgery</i> , 2021, 169, 708-720.	1.9	22
30	A pancreatic tail mass in a young male. <i>Gastroenterology</i> , 2021, , .	1.3	1
31	Cytology adds value to monoclonal antibody Das-1 testing for detection of high-risk pancreatic cysts. <i>Journal of the American Society of Cytopathology</i> , 2021, 10, 249-254.	0.5	4
32	Analysis of in court malpractice litigation following pancreatic surgery. <i>Pancreatology</i> , 2021, 21, 819-823.	1.1	2
33	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. <i>Pancreatology</i> , 2021, 21, 1119-1126.	1.1	13
34	The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysis. <i>Surgery</i> , 2021, 170, 1195-1204.	1.9	11
35	Abstract PO-097: Addition of losartan to FOLFIRINOX and chemoradiation reduces the expression of pro-invasive and immunosuppressive genes in locally-advanced pancreatic cancer. , 2021, , .		0
36	A Step-Up Approach to Infected Abdominal Fluid Collections: Not Just for Pancreatitis. <i>Surgical Infections</i> , 2020, 21, 54-61.	1.4	5

#	ARTICLE	IF	CITATIONS
37	Can Prognosis Be Modified in Pancreatic Cancer?. <i>Annals of Surgical Oncology</i> , 2020, 27, 632-633.	1.5	2
38	Prognostic Value of Pancreatic Fistula in Resected Patients With Pancreatic Cancer With Neoadjuvant Therapyâ€”Reply. <i>JAMA Surgery</i> , 2020, 155, 269.	4.3	2
39	Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. <i>Annals of Surgery</i> , 2020, 272, 357-365.	4.2	39
40	Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 125-131.	1.1	22
41	Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 1606-1612.	1.5	6
42	Does preoperative pharmacologic prophylaxis reduce the rate of venous thromboembolism in pancreatectomy patients?. <i>Hpb</i> , 2020, 22, 1020-1024.	0.3	9
43	Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 1400-1406.	1.5	22
44	Response to Comment on â€œReappraising the Concept of Conditional Survival After Pancreatectomy for Ductal Adenocarcinomaâ€•. <i>Annals of Surgery</i> , 2020, 271, e18-e19.	4.2	0
45	Reappraising the Concept of Conditional Survival After Pancreatectomy for Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2020, 271, 1148-1155.	4.2	19
46	Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2020, 49, 897-903.	1.1	10
47	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 5161-5172.	1.5	4
48	ASO Author Reflections: Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3913-3914.	1.5	1
49	Diagnosis of Depression is Associated with Readmission Following Elective Pancreatectomy. <i>Annals of Surgical Oncology</i> , 2020, 27, 4544-4550.	1.5	2
50	International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. <i>Pancreatology</i> , 2020, 20, 910-918.	1.1	39
51	Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. <i>Pancreatology</i> , 2020, 20, 722-728.	1.1	22
52	International consensus guidelines on interventional endoscopy in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. <i>Pancreatology</i> , 2020, 20, 1045-1055.	1.1	53
53	Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target. <i>Nature Communications</i> , 2020, 11, 3303.	12.8	55
54	Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. <i>Histopathology</i> , 2020, 77, 35-45.	2.9	9

#	ARTICLE	IF	CITATIONS
55	Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. <i>Histopathology</i> , 2020, 77, 144-155.	2.9	4
56	Guidelines on the histopathology of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and the European Pancreatic Club. <i>Pancreatology</i> , 2020, 20, 586-593.	1.1	47
57	Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. <i>American Journal of Surgery</i> , 2020, 220, 29-34.	1.8	19
58	Improved Mortality in Necrotizing Pancreatitis with a Multidisciplinary Minimally Invasive Step-Up Approach: Comparison with a Modern Open Necrosectomy Cohort. <i>Journal of the American College of Surgeons</i> , 2020, 230, 873-883.	0.5	30
59	Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. <i>Pancreatology</i> , 2020, 20, 691-697.	1.1	9
60	International Consensus Guidelines for Risk Factors in Chronic Pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. <i>Pancreatology</i> , 2020, 20, 579-585.	1.1	40
61	Management of the pancreatic transection plane after left (distal) pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). <i>Surgery</i> , 2020, 168, 72-84.	1.9	48
62	Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3898-3912.	1.5	13
63	Randomized trial of a perioperative geriatric intervention for older adults with cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12012-12012.	1.6	28
64	Single-nucleus RNA-seq of frozen archival primary pancreatic ductal adenocarcinoma uncovers multi-compartment intratumoral heterogeneity associated with neoadjuvant treatment.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4633-4633.	1.6	0
65	Patient-reported outcomes (PROs) in older adults with gastrointestinal (GI) cancer undergoing surgery.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24032-e24032.	1.6	0
66	Patient-reported outcomes (PROs) in older adults with gastrointestinal (GI) cancer undergoing surgery.. <i>Journal of Clinical Oncology</i> , 2020, 38, 159-159.	1.6	0
67	Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy. <i>JAMA Surgery</i> , 2019, 154, 943.	4.3	79
68	A multimodality test to guide the management of patients with a pancreatic cyst. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	129
69	Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions. <i>Gastroenterology</i> , 2019, 157, 720-730.e2.	1.3	44
70	Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. <i>Modern Pathology</i> , 2019, 32, 844-854.	5.5	4
71	Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). <i>Clinical Cancer Research</i> , 2019, 25, 2644-2655.	7.0	56
72	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. <i>JAMA Oncology</i> , 2019, 5, 1020.	7.1	353

#	ARTICLE	IF	CITATIONS
73	Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing. <i>American Journal of Gastroenterology</i> , 2019, 114, 1539-1549.	0.4	43
74	Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26835-26845.	7.1	69
75	Benchmarks in Pancreatic Surgery. <i>Annals of Surgery</i> , 2019, 270, 211-218.	4.2	202
76	Major Complications Independently Increase Long-Term Mortality After Pancreatoduodenectomy for Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1984-1990.	1.7	29
77	Lower phosphate levels following pancreatectomy is associated with postoperative pancreatic fistula formation. <i>Hpb</i> , 2019, 21, 834-840.	0.3	5
78	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. <i>Oncologist</i> , 2019, 24, 945-954.	3.7	13
79	Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. <i>Annals of Surgery</i> , 2019, 269, 733-740.	4.2	235
80	Number of Examined Lymph Nodes and Nodal Status Assessment in Distal Pancreatectomy for Body/Tail Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019, 270, 1138-1146.	4.2	50
81	Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC). <i>Annals of Surgery</i> , 2019, 270, 158-164.	4.2	44
82	Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.. <i>Journal of Clinical Oncology</i> , 2019, 37, 392-392.	1.6	2
83	Ex vivo human bile duct radiofrequency ablation with a bipolar catheter. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 2808-2813.	2.4	14
84	Hospital readmission after distal pancreatectomy is predicted by specific intra- and post-operative factors. <i>American Journal of Surgery</i> , 2018, 216, 511-517.	1.8	5
85	Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma. <i>JAMA Oncology</i> , 2018, 4, 963.	7.1	426
86	Feasibility and safety of microforceps biopsy in the diagnosis of pancreatic cysts. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 79-86.	1.0	66
87	Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas. <i>Annals of Surgery</i> , 2018, 267, 157-163.	4.2	105
88	Characterization and Optimal Management of High-risk Pancreatic Anastomoses During Pancreatoduodenectomy. <i>Annals of Surgery</i> , 2018, 267, 608-616.	4.2	117
89	Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 607-612.	1.3	32
90	Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 656-661.	1.3	13

#	ARTICLE	IF	CITATIONS
91	Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Annals of Surgery</i> , 2018, 268, 340-347.	4.2	39
92	Intraductal Papillary Mucinous Neoplasm of the Pancreas in Young Patients: Tumor Biology, Clinical Features, and Survival Outcomes. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 226-234.	1.7	16
93	Pancreatogastrostomy Vs. Pancreatojejunostomy: a Risk-Stratified Analysis of 5316 Pancreatoduodenectomies. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 68-76.	1.7	19
94	International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. <i>Pancreatology</i> , 2018, 18, 2-11.	1.1	452
95	Understanding Pancreatic Diseases Using Animated Pancreas Patient. <i>Pancreas</i> , 2018, 47, 1256-1261.	1.1	8
96	Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma?. <i>Annals of Surgical Oncology</i> , 2018, 25, 3936-3942.	1.5	10
97	Intraoperative Dexamethasone Decreases Infectious Complications After Pancreaticoduodenectomy and is Associated with Long-Term Survival in Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 4020-4026.	1.5	38
98	Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 4027-4034.	1.5	21
99	Surgical management of intraductal papillary mucinous neoplasm with main duct involvement: an international expert survey and case-vignette study. <i>Surgery</i> , 2018, 164, 17-23.	1.9	17
100	Mutant GNAS drives pancreatic tumorigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. <i>Nature Cell Biology</i> , 2018, 20, 811-822.	10.3	124
101	Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer. <i>JAMA Surgery</i> , 2018, 153, 809.	4.3	103
102	To resect or not to resect. <i>Current Opinion in Gastroenterology</i> , 2018, 34, 343-348.	2.3	4
103	Altered exocrine function can drive adipose wasting in early pancreatic cancer. <i>Nature</i> , 2018, 558, 600-604.	27.8	114
104	Potentially curative combination of TGF- $\beta$ 1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4116-4116.	1.6	9
105	Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 272-272.	1.6	7
106	Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis. <i>Gut</i> , 2017, 66, 495-506.	12.1	177
107	Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2017, 265, 185-191.	4.2	366
108	Cytologic characteristics of circulating epithelioid cells in pancreatic disease. <i>Cancer Cytopathology</i> , 2017, 125, 332-340.	2.4	30

#	ARTICLE	IF	CITATIONS
109	Imaging of pancreatic cystic lesions with confocal laser endomicroscopy: an ex vivo pilot study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 5119-5126.	2.4	7
110	Potential impact of a volume pledge on spatial access: A population-level analysis of patients undergoing pancreatectomy. <i>Surgery</i> , 2017, 162, 203-210.	1.9	40
111	Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 658-664.	1.7	32
112	Does Size Matter in Pancreatic Cancer?. <i>Annals of Surgery</i> , 2017, 266, 142-148.	4.2	89
113	Ductal Carcinoma Arising in a Largely Unchanged Presumed Branch-duct IPMN After 10 Years of Surveillance. <i>Annals of Surgery</i> , 2017, 266, e38-e40.	4.2	5
114	Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 5959-5969.	7.0	75
115	Post-Whipple imaging in patients with pancreatic ductal adenocarcinoma: association with overall survival: a multivariate analysis. <i>Abdominal Radiology</i> , 2017, 42, 2101-2107.	2.1	14
116	The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. <i>Surgery</i> , 2017, 161, 584-591.	1.9	2,655
117	Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma. <i>Pancreatology</i> , 2017, 17, 920-926.	1.1	37
118	Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center. <i>Gastroenterology</i> , 2017, 153, 1284-1294.e1.	1.3	189
119	Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. <i>Pancreatology</i> , 2017, 17, 738-753.	1.1	1,208
120	Primary lymph node gastrinoma: A single institution experience. <i>Surgery</i> , 2017, 162, 1088-1094.	1.9	12
121	Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment. <i>Pancreas</i> , 2017, 46, 183-189.	1.1	13
122	Health-related Quality of Life and Functional Outcomes in 5-year Survivors After Pancreaticoduodenectomy. <i>Annals of Surgery</i> , 2017, 266, 685-692.	4.2	57
123	Intraductal Papillary Mucinous Neoplasms of the Pancreas: Strategic Considerations. <i>Visceral Medicine</i> , 2017, 33, 466-476.	1.3	25
124	Reappraisal of Staging Laparoscopy for Patients with Pancreatic Adenocarcinoma: A Contemporary Analysis of 1001 Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 3203-3211.	1.5	37
125	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer (BRPC): Toxicity, R0 resection, and interim survival data from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4113-4113.	1.6	1
126	Phase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4118-4118.	1.6	5



#	ARTICLE	IF	CITATIONS
127	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study.. Journal of Clinical Oncology, 2017, 35, 368-368.	1.6	1
128	TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.. Journal of Clinical Oncology, 2017, 35, 386-386.	1.6	13
129	Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: Results of a decision analysis.. Journal of Clinical Oncology, 2017, 35, 4117-4117.	1.6	0
130	Intraductal Papillary Mucinous Neoplasm of the Pancreas. Annals of Surgery, 2016, 263, 908-917.	4.2	27
131	Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract. Annals of Surgery, 2016, 263, 162-177.	4.2	223
132	Preoperative biliary drainage does not increase major complications in pancreaticoduodenectomy: a large single center experience from the <scp>Massachusetts</scp> General Hospital. Journal of Hepato-Biliary-Pancreatic Sciences, 2016, 23, 181-187.	2.6	53
133	Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (â%20-mm Invasive Component). Annals of Surgery, 2016, 263, 793-801.	4.2	60
134	Risk-adjusted Outcomes of Clinically Relevant Pancreatic Fistula Following Pancreatoduodenectomy. Annals of Surgery, 2016, 264, 344-352.	4.2	144
135	Selective and reversible suppression of intestinal stem cell differentiation by pharmacological inhibition of BET bromodomains. Scientific Reports, 2016, 6, 20390.	3.3	19
136	Risk of pancreatic malignancy and mortality in branch-duct IPMNs undergoing surveillance: A systematic review and meta-analysis. Digestive and Liver Disease, 2016, 48, 473-479.	0.9	78
137	Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. Annals of Surgical Oncology, 2016, 23, 609-617.	1.5	24
138	Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. Clinical Cancer Research, 2016, 22, 4259-4270.	7.0	44
139	Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2016, 20, 953-959.	1.7	12
140	The value of KRAS mutation testing with CEA for the diagnosis of pancreatic mucinous cysts. Endoscopy International Open, 2016, 04, E391-E396.	1.8	28
141	Loss of Trefoil Factor 2 From Pancreatic Duct Glands Promotes Formation of Intraductal Papillary Mucinous Neoplasms in Mice. Gastroenterology, 2016, 151, 1232-1244.e10.	1.3	40
142	A multicenter randomized controlled trial comparing pancreatic leaks after TissueLink versus SEAMGUARD after distal pancreatectomy (PLATS) NCT01051856. Journal of Surgical Research, 2016, 206, 32-40.	1.6	16
143	Intraductal Papillary Mucinous Neoplasm of the Pancreas. Surgical Clinics of North America, 2016, 96, 1431-1445.	1.5	13
144	2016 American Pancreatic Association Presidential Address. Pancreas, 2016, 45, 1359-1360.	1.1	0

#	ARTICLE	IF	CITATIONS
145	Discordance Between Perioperative Antibiotic Prophylaxis and Wound Infection Cultures in Patients Undergoing Pancreaticoduodenectomy. <i>JAMA Surgery</i> , 2016, 151, 432.	4.3	95
146	Operative Versus Nonoperative Management of Nonfunctioning Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 277-283.	1.7	48
147	Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 140-148.	1.0	119
148	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 470-478.	7.0	168
149	The Characterization and Prediction of ISGPF Grade C Fistulas Following Pancreatoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 262-276.	1.7	108
150	A blinded assessment of video quality in wearable technology for telementoring in open surgery: the Google Glass experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2016, 30, 372-378.	2.4	54
151	Intraoperative radiotherapy (IORT) in the era of intensive neoadjuvant chemotherapy and chemoradiotherapy for locally advanced and borderline resectable adenocarcinoma of the pancreas (PDAC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 393-393.	1.6	1
152	Intraductal papillary mucinous neoplasms. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 424-429.	2.3	17
153	The Proteome of Postsurgical Pancreatic Juice. <i>Pancreas</i> , 2015, 44, 574-582.	1.1	15
154	IPMN Involving the Main Pancreatic Duct. <i>Annals of Surgery</i> , 2015, 261, 976-983.	4.2	114
155	Diagnosis and Management of Pancreatic Cystic Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 655-674.	2.2	21
156	Intraductal Papillary Mucinous Adenocarcinoma of the Pancreas: Clinical Outcomes, Prognostic Factors, and the Role of Adjuvant Therapy. <i>Visceral Medicine</i> , 2015, 31, 43-46.	1.3	8
157	Circulating Epithelial Cells in Patients with Pancreatic Lesions: Clinical and Pathologic Findings. <i>Journal of the American College of Surgeons</i> , 2015, 221, 699-707.	0.5	64
158	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. <i>Gastroenterology</i> , 2015, 149, 1501-1510.	1.3	376
159	Quality assessment of the guidelines on cystic neoplasms of the pancreas. <i>Pancreatology</i> , 2015, 15, 463-469.	1.1	19
160	Acute pancreatitis in intraductal papillary mucinous neoplasms: A common predictor of malignant intestinal subtype. <i>Surgery</i> , 2015, 158, 1219-1225.	1.9	42
161	Oncocytic-Type Intraductal Papillary Mucinous Neoplasms: A Unique Malignant Pancreatic Tumor with Good Long-Term Prognosis. <i>Journal of the American College of Surgeons</i> , 2015, 220, 839-844.	0.5	63
162	Effects of Comorbidities on Outcomes of Patients With Intraductal Papillary Mucinous Neoplasms. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1816-1823.	4.4	54

#	ARTICLE	IF	CITATIONS
163	The Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancer. <i>Surgery</i> , 2015, 157, 881-887.	1.9	91
164	Management of Pancreatic Cysts: The Evidence Is Not Here Yet. <i>Gastroenterology</i> , 2015, 148, 685-687.	1.3	41
165	Patterns of Recurrence After Resection of IPMN. <i>Annals of Surgery</i> , 2015, 262, 1108-1114.	4.2	101
166	Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer. <i>Annals of Surgery</i> , 2015, 261, 12-17.	4.2	717
167	Pancreatic duct glands (PDGs) are a progenitor compartment responsible for pancreatic ductal epithelial repair. <i>Stem Cell Research</i> , 2015, 15, 190-202.	0.7	59
168	The effect of antecolic versus retrocolic reconstruction on delayed gastric emptying after classic non-pylorus-preserving pancreaticoduodenectomy. <i>American Journal of Surgery</i> , 2015, 209, 1028-1035.	1.8	34
169	Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: an initial experience with histopathologic correlation. <i>International Journal of Nanomedicine</i> , 2014, 9, 1891.	6.7	28
170	Peritoneal seeding in intraductal papillary mucinous neoplasm of the pancreas patients who underwent endoscopic ultrasound-guided fine-needle aspiration: The PIPE Study. <i>Endoscopy</i> , 2014, 46, 382-387.	1.8	90
171	Cystic pancreatic neuroendocrine tumors: The value of cytology in preoperative diagnosis. <i>Cancer Cytopathology</i> , 2014, 122, 435-444.	2.4	59
172	Standardized cytopathology reporting for the pancreas: The time is right. <i>Cancer Cytopathology</i> , 2014, 122, 397-398.	2.4	5
173	Standardized terminology and nomenclature for pancreatobiliary cytology: The Papanicolaou Society of Cytopathology guidelines. <i>Diagnostic Cytopathology</i> , 2014, 42, 338-350.	1.0	181
174	Standardized terminology and nomenclature for pancreatobiliary cytology: The Papanicolaou Society of Cytopathology Guidelines. <i>CytoJournal</i> , 2014, 11, 15.	1.7	112
175	Mujer joven con tumoración quística en la cabeza pancreática. <i>Cirugía Española</i> , 2014, 92, 565-567.	0.2	0
176	Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2014, 110, 160-164.	0.6	25
177	A contemporary series of patients undergoing open debridement for necrotizing pancreatitis. <i>American Journal of Surgery</i> , 2014, 208, 324-331.	1.8	27
178	Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. <i>Practical Radiation Oncology</i> , 2014, 4, e117-e123.	2.1	4
179	A Young Woman With a Pancreatic Head Cystic Neoplasm. <i>Cirugía Española (English Edition)</i> , 2014, 92, 565-567.	0.1	0
180	Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: Implications of minimal involvement of the main pancreatic duct. <i>Surgery</i> , 2014, 156, 611-621.	1.9	65

#	ARTICLE	IF	CITATIONS
181	In response to Birgir Gudjonsson, MD. <i>Surgery</i> , 2014, 156, 1286.	1.9	1
182	Is It Safe to Follow Side Branch IPMNs?. <i>Advances in Surgery</i> , 2014, 48, 13-25.	1.3	18
183	A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 830-838.	0.8	101
184	Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4128-4128.	1.6	3
185	Lymphoepithelial cysts and cystic lymphangiomas: Under-recognized benign cystic lesions of the pancreas. <i>World Journal of Gastrointestinal Surgery</i> , 2014, 6, 136.	1.5	6
186	Natural History and Malignant Change of Main Duct IPMN. , 2014, , 11-17.		0
187	Timing of Resection of Main-Duct IPMN. , 2014, , 153-161.		0
188	Accurate Prediction of Nodal Status in Preoperative Patients with Pancreatic Ductal Adenocarcinoma Using Next-Gen Nanoparticle. <i>Translational Oncology</i> , 2013, 6, 670-675.	3.7	27
189	Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. <i>Cancer</i> , 2013, 119, 4196-4204.	4.1	58
190	Gastroenteropancreatic Neuroendocrine Tumors: Role of Imaging in Diagnosis and Management. <i>Radiology</i> , 2013, 266, 38-61.	7.3	156
191	NO/N1, PNL, or LNR? The Effect of Lymph Node Number on Accurate Survival Prediction in Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 257-266.	1.7	119
192	Diagnosis and Management of Cystic Pancreatic Lesions. <i>American Journal of Roentgenology</i> , 2013, 200, 343-354.	2.2	139
193	Pancreatic Cystic Neoplasms: Management and Unanswered Questions. <i>Gastroenterology</i> , 2013, 144, 1303-1315.	1.3	206
194	FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience. <i>Oncologist</i> , 2013, 18, 543-548.	3.7	265
195	Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2013, 257, 731-736.	4.2	344
196	Genetic, tissue, and plasma biomarkers of outcomes from a prospective study of neoadjuvant short course proton-based chemoradiation for resectable pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4047-4047.	1.6	0
197	Cystic Papillary Pattern in Pancreatic Ductal Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 696-701.	3.7	28
198	Evolution of the Whipple procedure at the Massachusetts General Hospital. <i>Surgery</i> , 2012, 152, S56-S63.	1.9	188

#	ARTICLE	IF	CITATIONS
199	International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. <i>Pancreatology</i> , 2012, 12, 183-197.	1.1	2,043
200	Intraductal papillary mucinous neoplasms: Does a family history of pancreatic cancer matter?. <i>Pancreatology</i> , 2012, 12, 358-363.	1.1	39
201	Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. <i>Arthritis and Rheumatism</i> , 2012, 64, 3061-3067.	6.7	630
202	Pancreatic ductal adenocarcinoma: Long-term survival does not equal cure. <i>Surgery</i> , 2012, 152, S43-S49.	1.9	182
203	Andrew L. Warshaw, MD: Modern pioneer of pancreatic surgery. <i>Surgery</i> , 2012, 152, S1-S3.	1.9	2
204	851 resected cystic tumors of the pancreas: A 33-year experience at the Massachusetts General Hospital. <i>Surgery</i> , 2012, 152, S4-S12.	1.9	355
205	Consensus statement on the pathology of IgG4-related disease. <i>Modern Pathology</i> , 2012, 25, 1181-1192.	5.5	2,171
206	Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. <i>Cancer</i> , 2012, 118, 3026-3035.	4.1	59
207	Immediate versus delayed adjuvant chemoradiation for resected pancreatic cancer: An analysis of local control and survival.. <i>Journal of Clinical Oncology</i> , 2012, 30, 301-301.	1.6	0
208	Phase I/II study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) followed by early surgery for resectable pancreatic ductal adenocarcinoma (PDAC) of the head.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4021-4021.	1.6	1
209	Cytology Adds Value to Imaging Studies for Risk Assessment of Malignancy in Pancreatic Mucinous Cysts. <i>Annals of Surgery</i> , 2011, 254, 977-983.	4.2	136
210	Open Pancreatic Necrosectomy: Indications in the Minimally Invasive Era. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 1089-1091.	1.7	7
211	Molecular characteristics and biological behaviours of the oncocytic and pancreatobiliary subtypes of intraductal papillary mucinous neoplasms. <i>Journal of Pathology</i> , 2011, 224, 508-516.	4.5	56
212	Interventional Radiology in the Management of Abdominal Collections After Distal Pancreatectomy: A Retrospective Review. <i>American Journal of Roentgenology</i> , 2011, 197, 241-246.	2.2	49
213	Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. <i>Gut</i> , 2011, 60, 1712-1720.	12.1	244
214	Twenty-Three Years of the Warshaw Operation for Distal Pancreatectomy With Preservation of the Spleen. <i>Annals of Surgery</i> , 2011, 253, 1136-1139.	4.2	123
215	Implications of Incidentally Discovered, Nonfunctioning Pancreatic Endocrine Tumors. <i>Archives of Surgery</i> , 2011, 146, 534.	2.2	208
216	Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy. <i>Gastrointestinal Cancer Research: GCR</i> , 2011, 4, 116-21.	0.7	9

#	ARTICLE	IF	CITATIONS
217	Invasive Intraductal Papillary Mucinous Carcinomas of the Pancreas. <i>Annals of Surgery</i> , 2010, 251, 477-482.	4.2	69
218	Novel Xenograft and Cell Line Derived From an Invasive Intraductal Papillary Mucinous Neoplasm of the Pancreas Give New Insights Into Molecular Mechanisms. <i>Pancreas</i> , 2010, 39, 308-314.	1.1	11
219	Does the Mechanism of Lymph Node Invasion Affect Survival in Patients with Pancreatic Ductal Adenocarcinoma?. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 261-267.	1.7	55
220	Pancreatic cysts. <i>Cancer Cytopathology</i> , 2010, 118, 1-13.	2.4	127
221	Incidental Pancreatic Cysts: Do We Really Know What We Are Watching?. <i>Pancreatology</i> , 2010, 10, 144-150.	1.1	212
222	Mucin-Producing Neoplasms of the Pancreas: An Analysis of Distinguishing Clinical and Epidemiologic Characteristics. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 213-219.e4.	4.4	289
223	Pancreatic Duct Glands Are Distinct Ductal Compartments That React to Chronic Injury and Mediate Shh-Induced Metaplasia. <i>Gastroenterology</i> , 2010, 138, 1166-1177.	1.3	162
224	Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Gastroenterology</i> , 2010, 139, 708-713.e2.	1.3	153
225	Management of Cystic Neoplasms of the Pancreas. , 2010, , 1125-1139.		0
226	Tumors of the Pancreas. , 2010, , 1017-1034.e4.		7
227	Fluid CEA in IPMNs: A Useful Test or the Flip of a Coin?. <i>American Journal of Gastroenterology</i> , 2009, 104, 796-797.	0.4	38
228	Current Trends in Pancreatic Cystic Neoplasms. <i>Archives of Surgery</i> , 2009, 144, 448.	2.2	144
229	Plectin-1 is a Biomarker of Malignant Pancreatic Intraductal Papillary Mucinous Neoplasms. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 1948-1954.	1.7	56
230	Comparative Performance of MDCT and MRI With MR Cholangiopancreatography in Characterizing Small Pancreatic Cysts. <i>American Journal of Roentgenology</i> , 2009, 193, 722-731.	2.2	163
231	The Inflammatory Pancreatic Head Mass. <i>Annals of Surgery</i> , 2009, 249, 105-110.	4.2	58
232	Global Genomic Analysis of Intraductal Papillary Mucinous Neoplasms of the Pancreas Reveals Significant Molecular Differences Compared to Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2009, 249, 440-447.	4.2	82
233	Mucinous Cystic Neoplasms. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 411-413.	1.7	61
234	Quality of Life in Pancreatic Cancer: Analysis by Stage and Treatment. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 783-794.	1.7	97

#	ARTICLE	IF	CITATIONS
235	Pancreatic Fistula Rates After 462 Distal Pancreatectomies: Staplers Do Not Decrease Fistula Rates. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 1691-1698.	1.7	225
236	Management of intraductal papillary mucinous neoplasms. <i>Current Gastroenterology Reports</i> , 2008, 10, 136-143.	2.5	21
237	Cystic Pancreatic Endocrine Neoplasms: A Distinct Tumor Type?. <i>Journal of the American College of Surgeons</i> , 2008, 206, 1154-1158.	0.5	152
238	Assessment of Pancreatic Tumor Resectability with Multidetector Computed Tomography. <i>Academic Radiology</i> , 2008, 15, 1058-1068.	2.5	13
239	Debridement and Closed Packing for Sterile or Infected Necrotizing Pancreatitis. <i>Annals of Surgery</i> , 2008, 247, 294-299.	4.2	290
240	Mucinous Cystic Neoplasm of the Pancreas is Not an Aggressive Entity. <i>Annals of Surgery</i> , 2008, 247, 571-579.	4.2	407
241	Improved Contemporary Surgical Management of Insulinomas. <i>Annals of Surgery</i> , 2008, 247, 165-172.	4.2	187
242	Surgical Management of IPMN. , 2008, , 419-432.		0
243	Pancreatic Cysts 3 cm or Smaller. <i>Radiology</i> , 2007, 243, 607-608.	7.3	3
244	Evolving Patterns in the Detection and Outcomes of Pancreatic Neuroendocrine Neoplasms. <i>Archives of Surgery</i> , 2007, 142, 347.	2.2	180
245	A Selective Approach to the Resection of Cystic Lesions of the Pancreas: Results From 539 Consecutive Patients. <i>Annals of Surgery</i> , 2007, 245, 826-827.	4.2	6
246	Middle Pancreatectomy. <i>Annals of Surgery</i> , 2007, 246, 69-76.	4.2	222
247	Branch-Duct Intraductal Papillary Mucinous Neoplasms: Observations in 145 Patients Who Underwent Resection. <i>Gastroenterology</i> , 2007, 133, 72-79.	1.3	422
248	In Vivo Lineage Tracing Defines the Role of Acinar-to-Ductal Transdifferentiation in Inflammatory Ductal Metaplasia. <i>Gastroenterology</i> , 2007, 133, 1999-2009.	1.3	251
249	Distal pancreatectomy with splenic preservation revisited. <i>Surgery</i> , 2007, 141, 619-625.	1.9	73
250	Consensus defining postpancreatectomy complications: An opportunity we cannot ignore. <i>Surgery</i> , 2007, 142, 771-772.	1.9	4
251	“How I do It”-Session of the Pancreas Club. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 725-725.	1.7	0
252	International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas. <i>Pancreatology</i> , 2006, 6, 17-32.	1.1	1,805

#	ARTICLE	IF	CITATIONS
253	Implications and Cost of Pancreatic Leak Following Distal Pancreatic Resection. Archives of Surgery, 2006, 141, 361.	2.2	111
254	Intraductal Papillary Mucinous Neoplasm of Pancreas: Multi-â€œDetector Row CT with 2D Curved Reformationsâ€œ Correlation with MRCP. Radiology, 2006, 238, 560-569.	7.3	199
255	Pancreatic Cysts 3 cm or Smaller: How Aggressive Should Treatment Be?. Radiology, 2006, 238, 912-919.	7.3	149
256	Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2006, 24, 2897-2902.	1.6	487
257	Histopathological Diagnosis of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary-Mucinous Neoplasms: Interobserver Agreement. Pancreas, 2005, 31, 344-349.	1.1	92
258	Endoscopic Ultrasound Guided Fine Needle Aspiration Biopsy of Autoimmune Pancreatitis. American Journal of Surgical Pathology, 2005, 29, 1464-1471.	3.7	168
259	Serous Cystadenoma of the Pancreas. Annals of Surgery, 2005, 242, 413-421.	4.2	341
260	Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Plea for Prospective Differentiation Between Main-Duct and Side-Branch Tumors. Annals of Surgical Oncology, 2005, 12, 98-99.	1.5	16
261	Cystic Pancreatic Lesions: A Simple Imaging-based Classification System for Guiding Management. Radiographics, 2005, 25, 1471-1484.	3.3	342
262	Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations. Pancreatology, 2005, 5, 67-74.	1.1	17
263	Choriocarcinoma involving the pancreas as first manifestation of a metastatic regressing mixed testicular germ cell tumor. Modern Pathology, 2004, 17, 1573-1580.	5.5	19
264	Cystic Neoplasms of the Pancreas. New England Journal of Medicine, 2004, 351, 1218-1226.	27.0	674
265	Cytokeratin 19 Is a Powerful Predictor of Survival in Pancreatic Endocrine Tumors. American Journal of Surgical Pathology, 2004, 28, 1145-1153.	3.7	107
266	Main-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery, 2004, 239, 678-687.	4.2	681
267	Membrane-bound ICAM-1 is upregulated by trypsin and contributes to leukocyte migration in acute pancreatitis. American Journal of Physiology - Renal Physiology, 2004, 287, G1194-G1199.	3.4	36
268	Pylorus-preserving Pancreaticoduodenectomy in the Treatment of Chronic Pancreatitis. World Journal of Surgery, 2003, 27, 1211-1216.	1.6	68
269	Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature, 2003, 425, 851-856.	27.8	1,395
270	Incidental Pancreatic Cysts. Archives of Surgery, 2003, 138, 427.	2.2	515



#	ARTICLE	IF	CITATIONS
271	Ductulo-insular Pancreatic Endocrine Neoplasms. American Journal of Surgical Pathology, 2003, 27, 461-468.	3.7	29
272	Giant Lipoma of the Pancreas: Case Report and Review of Lipomatous Lesions of the Pancreas. Pancreas, 2003, 26, 97-99.	1.1	23
273	Animal Models of Pancreatic Adenocarcinoma. , 2002, , 323-330.		0
274	Matrix metalloproteinase-9 promotes neutrophil migration and alveolar capillary leakage in pancreatitis-associated lung injury in the rat. Gastroenterology, 2002, 122, 188-201.	1.3	172
275	Complete dorsal pancreatectomy with preservation of the ventral pancreas: A new surgical technique. Surgery, 2002, 131, 577-580.	1.9	33
276	Surgery of cystic neoplasms. Gastrointestinal Endoscopy Clinics of North America, 2002, 12, 803-812.	1.4	4
277	Evaluation of Morphology and Microcirculation of the Pancreas by ex vivo and in vivo Reflectance Confocal Microscopy. Pancreatology, 2001, 1, 48-57.	1.1	18
278	Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients. Surgery, 2001, 129, 537-546.	1.9	86
279	Cystic Neoplasms of the Pancreas. Pancreatology, 2001, 1, 641-647.	1.1	46
280	Expression of the Adhesion Molecules Mac-1 and I-Selectin on Neutrophils in Acute Pancreatitis is Protease- and Complement-Dependent. Annals of Surgery, 2001, 233, 371-378.	4.2	35
281	Promoting Effect of a High-Fat/High-Protein Diet in DMBA-Induced Ductal Pancreatic Cancer in Rats. Annals of Surgery, 2001, 233, 688-695.	4.2	37
282	Telomerase Activity in Periampullary Tumors Correlates With Aggressive Malignancy. Annals of Surgery, 2001, 234, 344-351.	4.2	24
283	Effect of Matrix Metalloproteinase Inhibition on Pancreatic Cancer Invasion and Metastasis. Annals of Surgery, 2000, 231, 644-654.	4.2	60
284	Outcome of Pancreaticoduodenectomy With Pylorus Preservation or With Antrectomy in the Treatment of Chronic Pancreatitis. Annals of Surgery, 2000, 231, 293-300.	4.2	205
285	Cystic lesions in the pancreas: When to watch, when to resect. Current Gastroenterology Reports, 2000, 2, 152-158.	2.5	45
286	Laparoscopy and peritoneal cytology in the staging of pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Surgery, 2000, 7, 15-20.	2.0	79
287	Immunohistochemical Characterization of Pancreatic Tumors Induced by Dimethylbenzanthracene in Rats. American Journal of Pathology, 1999, 154, 1223-1229.	3.8	54
288	Specific Therapy for Local and Systemic Complications of Acute Pancreatitis With Monoclonal Antibodies Against ICAM-1. Annals of Surgery, 1999, 229, 834.	4.2	115

#	ARTICLE	IF	CITATIONS
289	Sequential Accumulation of K-ras Mutations and p53 Overexpression in the Progression of Pancreatic Mucinous Cystic Neoplasms to Malignancy. <i>Annals of Surgery</i> , 1999, 230, 501.	4.2	168
290	Lexipafant Fails to Improve Survival in Severe Necrotizing Pancreatitis in Rats. <i>International Journal of Gastrointestinal Cancer</i> , 1998, 23, 101-106.	0.4	26
291	Middle Segment Pancreatectomy. <i>Archives of Surgery</i> , 1998, 133, 327-31.	2.2	157
292	Subcellular kinetics of early trypsinogen activation in acute rodent pancreatitis. <i>American Journal of Physiology - Renal Physiology</i> , 1998, 274, G71-G79.	3.4	30
293	Technetium-99m-Labeled White Blood Cells. <i>Annals of Surgery</i> , 1998, 227, 86-94.	4.2	53
294	Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia. <i>Surgery</i> , 1997, 121, 42-49.	1.9	78
295	A rat model of pancreatic ductal adenocarcinoma: Targeting chemical carcinogens. <i>Surgery</i> , 1997, 122, 82-90.	1.9	49
296	Urinary trypsinogen activation peptide (TAP) predicts severity in patients with acute pancreatitis. <i>International Journal of Gastrointestinal Cancer</i> , 1997, 21, 105-110.	0.4	72
297	Pancreatic Mucinous Ductal Ectasia and Intraductal Papillary Neoplasms. <i>Annals of Surgery</i> , 1997, 225, 637-646.	4.2	133
298	Prevalence of Activating K-ras Mutations in the Evolutionary Stages of Neoplasia in Intraductal Papillary Mucinous Tumors of the Pancreas. <i>Annals of Surgery</i> , 1997, 226, 491-500.	4.2	183
299	Surgical Approaches to Benign and Malignant Tumors of the Ampulla of Vater. <i>Surgical Oncology Clinics of North America</i> , 1996, 5, 689-711.	1.5	3
300	Pathogenesis and Prevention of Early Pancreatic Infection in Experimental Acute Necrotizing Pancreatitis. <i>Annals of Surgery</i> , 1995, 222, 179-185.	4.2	108
301	Cystic Tumors of the Pancreas. <i>Surgical Clinics of North America</i> , 1995, 75, 1001-1016.	1.5	212
302	Increased Intrapancreatic Trypsinogen Activation in Ischemia-Induced Experimental Pancreatitis. <i>Annals of Surgery</i> , 1995, 221, 364-371.	4.2	46
303	Standards for Pancreatic Resection in the 1990s. <i>Archives of Surgery</i> , 1995, 130, 295.	2.2	420
304	Hypercalcemia causes acute pancreatitis by pancreatic secretory block, intracellular zymogen accumulation, and acinar cell injury. <i>American Journal of Surgery</i> , 1995, 169, 167-172.	1.8	45
305	Acute hypercalcemia causes acute pancreatitis and ectopic trypsinogen activation in the rat. <i>Gastroenterology</i> , 1995, 109, 239-246.	1.3	121
306	A rat model to study hypercalcemia-induced acute pancreatitis. <i>International Journal of Gastrointestinal Cancer</i> , 1994, 15, 91-96.	0.4	9

#	ARTICLE	IF	CITATIONS
307	Time Course of Bacterial Infection of the Pancreas and Its Relation to Disease Severity in a Rodent Model of Acute Necrotizing Pancreatitis. <i>Annals of Surgery</i> , 1994, 220, 193-198.	4.2	40
308	Hyperoncotic ultrahigh molecular weight dextran solutions reduce trypsinogen activation, prevent acinar necrosis, and lower mortality in rodent pancreatitis. <i>American Journal of Surgery</i> , 1993, 165, 40-45.	1.8	52
309	Trypsinogen-activation peptides in experimental rat pancreatitis: Prognostic implications and histopathologic correlates. <i>Gastroenterology</i> , 1992, 103, 1009-1016.	1.3	96
310	Pancreatic Carcinoma. <i>New England Journal of Medicine</i> , 1992, 326, 455-465.	27.0	1,391
311	Risk Factors for Pancreatic Cellular Injury after Cardiopulmonary Bypass. <i>New England Journal of Medicine</i> , 1991, 325, 382-387.	27.0	235
312	Pancreatic Cancer and Androgen Metabolism. <i>Pancreas</i> , 1990, 5, 515-518.	1.1	21
313	Surgical Treatment and Long-Term Outcome of Cystic Neoplasms of the Pancreas. , 0, , 932-939.		0
314	Surgical Management of Necrotizing Pancreatitis. , 0, , 308-320.		0
315	Clinical Assessment and Staging of Pancreatic Cancer. , 0, , 643-647.		0